Inhaled Furosemide for Transient Tachypnea of Newborn

Inhaled Furosemide for Transient Tachypnea of Newborn

This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.

Inclusion Criteria:

• Neonates with 34+0-39+0 gestational age
• on the first day of life
• with the clinical diagnosis of Transient Tachypnoea
• need for CPAP >6 hours to obtain the oxygen saturation >92%

Exclusion Criteria:

• Systemic infection
• Intubation and mechanical ventilation before Inclusion in the trail
• Malformation and any other disease with disturb of respiratory system